Cancer immunotherapy: Co-stimulatory agonists and co-inhibitory antagonists Journal Article
| Authors: | Peggs, K. S.; Quezada, S. A.; Allison, J. P. |
| Article Title: | Cancer immunotherapy: Co-stimulatory agonists and co-inhibitory antagonists |
| Abstract: | The generation and maintenance of immune responses are controlled by both co-stimulatory and co-inhibitory signalling through T cell co-receptors, many of which belong to the immunoglobulin-like superfamily or the tumour necrosis factor receptor superfamily. Agonistic or antagonistic monoclonal antibodies targeting these co-receptors have the potential to enhance immunity. Furthermore, their activity on the immunosuppressive regulatory T cell populations which are prevalent within many tumours provides an additional rationale for their use as anti-cancer therapies. This review summarizes the interactions between cancer and the immune system, highlighting the ways in which these new classes of immunostimulatory antibodies might enhance anti-tumour immunity and summarizing early clinical experience with their use. © 2009 British Society for Immunology. |
| Keywords: | unclassified drug; review; squamous cell carcinoma; drug potentiation; nonhuman; unspecified side effect; neoplasms; t lymphocyte; animals; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; dendritic cell vaccine; interleukin 2; ipilimumab; ticilimumab; unindexed drug; cancer immunotherapy; cancer prevention; melanoma; cytotoxicity; kidney carcinoma; monoclonal antibody; pancreas carcinoma; t lymphocyte receptor; regulatory t lymphocyte; lymphocyte activation; antibodies, monoclonal; fibrosarcoma; immunotherapy; tumor necrosis factor-alpha; cancer vaccine; t-lymphocytes, regulatory; breast carcinoma; cpg oligodeoxynucleotide; cancer immunization; cytotoxic t lymphocyte; ovary carcinoma; tumor immunity; cytokine production; autoimmunity; innate immunity; dna vaccine; adenovirus vector; ctla-4; antigens, cd; peptide vaccine; colon carcinoma; cytotoxic t lymphocyte antigen 4; tumor rejection; humoral immunity; t lymphocyte subpopulation; cd134 antigen; t lymphocyte activation; cd28 antigen; cd27 antigen; regulatory t cells; prostate carcinoma; antibody dependent cellular cytotoxicity; co-inhibition; co-stimulation; bms 663513; cd30 antigen; dihomo gamma linolenic acid; glucocorticoid induced tumor necrosis factor receptor antibody; glucocorticoid induced tumor necrosis factor receptor ligand; inducible t cell costimulator; monoclonal antibody cd134; monoclonal antibody cd137; monoclonal antibody cd274; monoclonal antibody cd279; ox40 ligand; tgn 1412; complement dependent cytoxicity; immunoglobulins |
| Journal Title: | Clinical and Experimental Immunology |
| Volume: | 157 |
| Issue: | 1 |
| ISSN: | 0009-9104 |
| Publisher: | British Society for Immunology |
| Date Published: | 2009-07-01 |
| Start Page: | 9 |
| End Page: | 19 |
| Language: | English |
| DOI: | 10.1111/j.1365-2249.2009.03912.x |
| PUBMED: | 19659765 |
| PROVIDER: | scopus |
| PMCID: | PMC2710587 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 4" - "Export Date: 30 November 2010" - "CODEN: CEXIA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work